It was reported that Bisphenol A, an endocrine disruptor, could increase the relative risk of both CVD and NAFLD by inducing pro-inflammatory activities and overproduction of interleukin 1β (IL-1β) and IL-6 [31]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.